Hoth Therapeutics Inc
NASDAQ:HOTH
Hoth Therapeutics Inc
Total Current Assets
Hoth Therapeutics Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
Total Current Assets
$8.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Assets
$55.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Assets
$29.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Assets
$42.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Assets
$43.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Assets
$55.6B
|
CAGR 3-Years
46%
|
CAGR 5-Years
26%
|
CAGR 10-Years
16%
|
|
Hoth Therapeutics Inc
Glance View
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2019-02-15. The firm is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The Company’s preclinical assets for atopic dermatitis; treatment for asthma and allergies using inhalational administration; a treatment for lung diseases resulting from bacterial infections, and treatment for inflammatory bowel diseases. The firm is also developing a diagnostic device via a mobile device. Its primary development products include HT-001, HT-KIT and HT-ALZ. Its preclinical development products include HT-003, HT-004, HT-006 and HT-002. The company is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.
See Also
What is Hoth Therapeutics Inc's Total Current Assets?
Total Current Assets
8.9m
USD
Based on the financial report for Sep 30, 2025, Hoth Therapeutics Inc's Total Current Assets amounts to 8.9m USD.
What is Hoth Therapeutics Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
10%
Over the last year, the Total Current Assets growth was 8%. The average annual Total Current Assets growth rates for Hoth Therapeutics Inc have been -2% over the past three years , 10% over the past five years .
